WEDNESDAY March 10th

• 12:30 - 13:00 EIGER BIOPHARMACEUTICALS SYMPOSIUM

• Hepatitis Delta: What the future holds ? Tarik ASSELAH (France) Pietro LAMPERTICO (Italy)

• The present state of hepatitis Delta: epidemiology, diagnosis, and current treatments - Tarik ASSELAH (France)

• Can current research change the face of hepatitis Delta ? - Ohad ETZION (Israel)

• D-LIVR patient characteristics - Pietro LAMPERTICO (Italy)

• Audience Q&A

• 13:00 - 13:05 INTRODUCTION

  Chairman:

  Patrick MARCELLIN (France)

• 13:05 - 14:10 NAFLD/NASH: PHYSIOPATHOLOGY, DIAGNOSIS AND OUTCOME

  Chairs :

  Michael MANNS (Germany) Massimo PINZANI (UK)

• Physiopathology of NAFLD and NASH - Massimo PINZANI (UK) Download

• Natural history of NASH and HCC - Elisabetta BUGIANESI (Italy) Download

• Non-invasive markers in NAFLD - Laurent CASTERA (France)

• How to make NAFLD a global public health priority ? - Jeffrey LAZARUS (Spain) Download

• 14:10 - 14:30 Pathology of NAFLD/NASH revisited

  Chairman:

  Valérie PARADIS (France) Download

• 14:30 - 14:40 BREAK & VISIT OF THE BOOTHS

• 14:40 - 15:50 NAFLD/NASH: MULTIDISCIPLINARY MANAGEMENT OF A SYSTEMIC DISEASE

  Chairs :

  Francesco NEGRO (Switzerland) Lawrence SERFATY (France)

• The hepatologists - Ana Carolina CARDOSO (Brazil) Download

• - Manuel ROMERO GOMEZ (Spain)

• The diabetologist - Michael RODEN (Germany)

• The surgeon - François PATTOU (France) Download

• DISCUSSION

• 15:50 - 16:10 STATE OF THE ART LECTURE

• New drugs for NASH - Arun SANYAL (USA)

• 16:10 - 16:20 BREAK & VISIT OF THE BOOTHS

• 16:20 - 17:20 END STAGE LIVER DISEASE

  Chairs :

  Shiv SARIN (India) Richard MOREAU (France)

• Management of hepatorenal syndrome - Adrian GADANO (Argentina) Download

• Is encephalopathy under-estimated ? - Dominique THABUT (France)

• Acute-on-chronic liver failure - François DURAND (France)

• DISCUSSION

• 17:20 - 17:40 STATE OF THE ART LECTURE

• Optimal management of cholangiocarcinoma - Ulrich BEUERS (Netherlands) Download

• 17:40 - 17:50 BREAK & VISIT OF THE BOOTHS

• 17:50 - 19:20 R&D : THE DRUGS PIPELINE PRESENTED BY COMPANIES

  Chairs :

  Arun SANYAL (USA) Raymond SCHINAZI (USA)

• Gilead’s Commitment to Liver disease - Tram TRAN (USA)

• Madrigal: Advancing Resmetirom in Phase 3 Trials for Non-cirrhotic NASH with Liver Fibrosis Rebecca TAUB, President of Research & Development - Rebecca TAUB (USA)

• Pfizer interest in NASH Dominique MENUET (France) Fady NTANIOS (USA)

• Assembly Biosciences: Developing Innovative Therapeutics Targeting Chronic HBV Infection - Luisa STAMM (USA)

• Eiger BioPharmaceuticals: Developing Two Foundational Treatments for HDV - Jeffrey GLENN (USA)

• Janssen

• 19:20 - 19:30 THE BEST POSTER PRICE

  Chairman:

  Patrick MARCELLIN (France)

• 19:30 - 19:50 TAKE HOME MESSAGES

  Chairman:

  Michael FRIED (USA)

• 19:50 - 20:00 CONCLUSION

  Chairman:

  Patrick MARCELLIN (France)